147 related articles for article (PubMed ID: 38765013)
1. Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity.
Liu W; Yu J; Sun K; Song Q; Li Y; He Y; Wang Y; Xu G; Wang C; Chen B
Front Immunol; 2024; 15():1410457. PubMed ID: 38765013
[TBL] [Abstract][Full Text] [Related]
2. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
van de Donk NWCJ; Usmani SZ
Front Immunol; 2018; 9():2134. PubMed ID: 30294326
[TBL] [Abstract][Full Text] [Related]
3. Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity.
Hiemstra IH; Santegoets KCM; Janmaat ML; De Goeij BECG; Ten Hagen W; van Dooremalen S; Boross P; van den Brakel J; Bosgra S; Andringa G; van Kessel-Welmers B; Verzijl D; Hibbert RG; Frerichs KA; Mutis T; van de Donk NWCJ; Ahmadi T; Satijn D; Sasser AK; Breij ECW
EBioMedicine; 2023 Jul; 93():104663. PubMed ID: 37379657
[TBL] [Abstract][Full Text] [Related]
4. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Kassem S; Diallo BK; El-Murr N; Carrié N; Tang A; Fournier A; Bonnevaux H; Nicolazzi C; Cuisinier M; Arnould I; Sidhu SS; Corre J; Avet-Loiseau H; Teillaud JL; van de Velde H; Wiederschain D; Chiron M; Martinet L; Virone-Oddos A
Blood; 2022 Feb; 139(8):1160-1176. PubMed ID: 35201323
[TBL] [Abstract][Full Text] [Related]
5. Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.
Manna A; Aulakh S; Jani P; Ahmed S; Akhtar S; Coignet M; Heckman M; Meghji Z; Bhatia K; Sharma A; Sher T; Alegria V; Malavasi F; Chini EN; Chanan-Khan A; Ailawadhi S; Paulus A
Clin Cancer Res; 2019 Jul; 25(13):3974-3985. PubMed ID: 30940652
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
7. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
8. Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity.
Yu T; Qiao C; Lv M; Tang L
BMC Biotechnol; 2019 May; 19(1):28. PubMed ID: 31118070
[TBL] [Abstract][Full Text] [Related]
9. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
[No Abstract] [Full Text] [Related]
10. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.
Paulus A; Manna A; Akhtar S; Paulus SM; Sharma M; Coignet MV; Jiang L; Roy V; Witzig TE; Ansell SM; Allan J; Furman R; Aulakh S; Manochakian R; Ailawadhi S; Chanan-Khan AA; Sher T
Br J Haematol; 2018 Oct; 183(2):196-211. PubMed ID: 30080238
[TBL] [Abstract][Full Text] [Related]
11. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma.
Panaampon J; Kariya R; Okada S
Cancer Immunol Immunother; 2022 May; 71(5):1017-1031. PubMed ID: 34545416
[TBL] [Abstract][Full Text] [Related]
13. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
[TBL] [Abstract][Full Text] [Related]
14. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
Zhu C; Song Z; Wang A; Srinivasan S; Yang G; Greco R; Theilhaber J; Shehu E; Wu L; Yang ZY; Passe-Coutrin W; Fournier A; Tai YT; Anderson KC; Wiederschain D; Bahjat K; Adrián FJ; Chiron M
Front Immunol; 2020; 11():1771. PubMed ID: 32922390
[TBL] [Abstract][Full Text] [Related]
15. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
16. Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma.
Saltarella I; Desantis V; Melaccio A; Solimando AG; Lamanuzzi A; Ria R; Storlazzi CT; Mariggiò MA; Vacca A; Frassanito MA
Cells; 2020 Jan; 9(1):. PubMed ID: 31936617
[TBL] [Abstract][Full Text] [Related]
17. The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.
Matas-Céspedes A; Vidal-Crespo A; Rodriguez V; Villamor N; Delgado J; Giné E; Roca-Ho H; Menéndez P; Campo E; López-Guillermo A; Colomer D; Roué G; Wiestner A; Parren PW; Doshi P; van Bueren JL; Pérez-Galán P
Clin Cancer Res; 2017 Mar; 23(6):1493-1505. PubMed ID: 27637890
[No Abstract] [Full Text] [Related]
18. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
Sanchez L; Wang Y; Siegel DS; Wang ML
J Hematol Oncol; 2016 Jun; 9(1):51. PubMed ID: 27363983
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
Martin TG; Corzo K; Chiron M; Velde HV; Abbadessa G; Campana F; Solanki M; Meng R; Lee H; Wiederschain D; Zhu C; Rak A; Anderson KC
Cells; 2019 Nov; 8(12):. PubMed ID: 31779273
[TBL] [Abstract][Full Text] [Related]
20. The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.
Moreno L; Perez C; Zabaleta A; Manrique I; Alignani D; Ajona D; Blanco L; Lasa M; Maiso P; Rodriguez I; Garate S; Jelinek T; Segura V; Moreno C; Merino J; Rodriguez-Otero P; Panizo C; Prosper F; San-Miguel JF; Paiva B
Clin Cancer Res; 2019 May; 25(10):3176-3187. PubMed ID: 30692097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
